Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

scientific article published in November 2001

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia is …
instance of (P31):
scholarly articleQ13442814
meta-analysisQ815382

External links are
P356DOI10.1016/S0090-4295(01)01344-9
P698PubMed publication ID11711348

P50authorPeter BoyleQ2074086
P2093author name stringRoehrborn CG
Robertson C
Padley RJ
Manski R
P2860cites workThe American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological AssociationQ33846043
Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasiaQ33895865
Medical therapy for benign prostatic hyperplasia: a review of the literatureQ33946113
A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic HyperplasiaQ38533290
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasiaQ39421840
Benign prostatic hyperplasia. Current pharmacological treatmentQ39489093
Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trialQ39498971
alpha-blockade in the treatment of symptomatic benign prostatic hyperplasiaQ40403192
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasiaQ40488158
Meta-analysis of published clinical trials of a ribosomal vaccine (ribomunyl) in prevention of respiratory infectionsQ44902153
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study GroupQ45335490
Bayesian approaches to random-effects meta-analysis: a comparative study.Q52320769
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.Q53628573
Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.Q54637719
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trialsQ56995126
Validation of a symptoms questionnaire for benign prostatic hyperplasiaQ67464054
Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in ItalyQ67465973
A general parametric approach to the meta-analysis of randomized clinical trialsQ67861093
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research GroupQ71678289
Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment TrialQ73807682
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)717-722
P577publication date2001-11-01
P1433published inUrologyQ7900884
P1476titleMeta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia
P478volume58

Reverse relations

cites work (P2860)
Q53288113A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia.
Q36852683A review of combination therapy in patients with benign prostatic hyperplasia
Q44696102Comprehensive analysis of clinical trials data shows unequivocally that Phosphodiesterase Inhibitors (PDEi) improve orgasm. The power of meta-analysis?
Q33961645Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
Q64928433Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study.
Q34643351Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia
Q24795452Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials
Q36542846How do I treat and follow my TUNA patients
Q36511604Management of bladder, prostatic and pelvic floor disorders
Q52407108Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination.
Q33588534Medical treatment of benign prostatic hyperplasia
Q44951587Meta-analysis: creating a level playing field for the patient with symptomatic benign prostatic hyperplasia?
Q34639437Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Q47352521Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia
Q39312097Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results
Q39392083Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study
Q24234560Terazosin for benign prostatic hyperplasia
Q30880131Terazosin for benign prostatic hyperplasia.
Q35855002The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia
Q35185800The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia
Q37323301The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia